Show simple item record

dc.contributor.authorBusch, Susann
dc.contributor.authorRydén, L
dc.contributor.authorStål, O
dc.contributor.authorJirström, K
dc.contributor.authorLandberg, Göran
dc.date.accessioned2012-12-13T14:50:54Z
dc.date.available2012-12-13T14:50:54Z
dc.date.issued2012
dc.identifier.citationLow ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer. 2012, 7 (9):e45669 PLoS ONEen_GB
dc.identifier.issn1932-6203
dc.identifier.pmid23029174
dc.identifier.doi10.1371/journal.pone.0045669
dc.identifier.urihttp://hdl.handle.net/10541/262494
dc.description.abstractThe aim of this study was to evaluate ERK phosphorylation as a stromal biomarker for breast cancer prognosis and tamoxifen treatment prediction within a randomized tamoxifen trial.
dc.language.isoenen
dc.rightsArchived with thanks to PloS oneen_GB
dc.titleLow ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer.en
dc.typeArticleen
dc.contributor.departmentBreakthrough Breast Cancer Research Unit, School of Cancer, Enabling Sciences and Technology, University of Manchester, Manchester Academic Health Science Centre, Paterson Institute for Cancer Research, The Christie NHS Foundation Trust, Manchester, United Kingdom.en_GB
dc.identifier.journalPloS Oneen_GB
html.description.abstractThe aim of this study was to evaluate ERK phosphorylation as a stromal biomarker for breast cancer prognosis and tamoxifen treatment prediction within a randomized tamoxifen trial.


This item appears in the following Collection(s)

Show simple item record